ID

30939

Description

Immunoregulation by Controlled Parasite Exposure in Multiple Sclerosis.; ODM derived from: https://clinicaltrials.gov/show/NCT00630383

Lien

https://clinicaltrials.gov/show/NCT00630383

Mots-clés

  1. 05/07/2018 05/07/2018 -
Détendeur de droits

See clinicaltrials.gov

Téléchargé le

5 juillet 2018

DOI

Pour une demande vous connecter.

Licence

Creative Commons BY 4.0

Modèle Commentaires :

Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.

Groupe Item commentaires pour :

Item commentaires pour :

Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.

Eligibility Multiple Sclerosis NCT00630383

Eligibility Multiple Sclerosis NCT00630383

Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
1. patients with documented multiple sclerosis relapsing remitting or secondary progressive with relapses, according to mcdonald's criteria, and an mri scan consistent with ms according to fazekas criteria
Description

Multiple Sclerosis, Relapsing-Remitting | Secondary Progressive Multiple Sclerosis Associated with Relapses | MRI scan Consistent with Multiple Sclerosis

Type de données

boolean

Alias
UMLS CUI [1]
C0751967
UMLS CUI [2,1]
C0751965
UMLS CUI [2,2]
C0332281
UMLS CUI [2,3]
C0035020
UMLS CUI [3,1]
C0024485
UMLS CUI [3,2]
C0332290
UMLS CUI [3,3]
C0026769
2. patients with at least 1 relapse in the last 12 months
Description

Relapse Quantity

Type de données

boolean

Alias
UMLS CUI [1,1]
C0035020
UMLS CUI [1,2]
C1265611
3. patients with edss score in the range of 0 to 5.5 at the baseline visit
Description

EDSS

Type de données

boolean

Alias
UMLS CUI [1]
C0451246
4. patients of both genders, age >18 years and < 60 years
Description

Age

Type de données

boolean

Alias
UMLS CUI [1]
C0001779
5. women of child bearing potential, (who have a negative pregnancy test) must agree to use methods of medically acceptable forms of contraception during the study.
Description

Childbearing Potential Pregnancy test negative | Childbearing Potential Contraceptive methods

Type de données

boolean

Alias
UMLS CUI [1,1]
C3831118
UMLS CUI [1,2]
C0427780
UMLS CUI [2,1]
C3831118
UMLS CUI [2,2]
C0700589
6. be able and willing to comply with study visits and procedures per protocol.
Description

Protocol Compliance

Type de données

boolean

Alias
UMLS CUI [1]
C0525058
7. understand, sign, and date the written voluntary informed consent form at the screening visit prior to any protocol-specific procedures performed.
Description

Informed Consent

Type de données

boolean

Alias
UMLS CUI [1]
C0021430
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
no populations at risk of severe illness or death will be included in this study
Description

At risk Illness Severe | At risk Death

Type de données

boolean

Alias
UMLS CUI [1,1]
C1444641
UMLS CUI [1,2]
C0221423
UMLS CUI [1,3]
C0205082
UMLS CUI [2,1]
C1444641
UMLS CUI [2,2]
C0011065
1. life expectancy < 6 months.
Description

Life Expectancy

Type de données

boolean

Alias
UMLS CUI [1]
C0023671
2. patient is < 5 years free of malignancy, except treated basal cell skin cancer or cervical carcinoma in situ.
Description

Malignant Neoplasms Free of Duration | Exception Basal cell carcinoma | Exception Carcinoma in situ of uterine cervix

Type de données

boolean

Alias
UMLS CUI [1,1]
C0006826
UMLS CUI [1,2]
C0332296
UMLS CUI [1,3]
C0449238
UMLS CUI [2,1]
C1705847
UMLS CUI [2,2]
C0007117
UMLS CUI [3,1]
C1705847
UMLS CUI [3,2]
C0851140
3. patient with grade iii/iv cardiac problems as defined by the new york heart association criteria. (i.e., congestive heart failure, myocardial infarction within 6 months of study)
Description

Cardiac problem New York Heart Association Classification | Congestive heart failure | Myocardial Infarction

Type de données

boolean

Alias
UMLS CUI [1,1]
C0262402
UMLS CUI [1,2]
C1275491
UMLS CUI [2]
C0018802
UMLS CUI [3]
C0027051
4. patients with severe and/or uncontrolled medical condition.
Description

Medical condition Severe Uncontrolled | Medical condition Uncontrolled

Type de données

boolean

Alias
UMLS CUI [1,1]
C3843040
UMLS CUI [1,2]
C0205082
UMLS CUI [1,3]
C0205318
UMLS CUI [2,1]
C3843040
UMLS CUI [2,2]
C0205318
5. patient has a known diagnosis of human immunodeficiency virus (hiv) infection.
Description

HIV Infection

Type de données

boolean

Alias
UMLS CUI [1]
C0019693
6. anaemia (hb <10 g/dl for females, <11 g/dl for males)
Description

Anemia | Hemoglobin measurement | Gender

Type de données

boolean

Alias
UMLS CUI [1]
C0002871
UMLS CUI [2]
C0518015
UMLS CUI [3]
C0079399
7. prior or present evidence of parasitic infection; prior treatment with anti-helminthic drugs
Description

Parasitic infection | Anthelmintics

Type de données

boolean

Alias
UMLS CUI [1]
C0747256
UMLS CUI [2]
C0003158
8. patient with serious medical or psychiatric illness that could potentially interfere with the completion of the study treatment according to this protocol
Description

Illness Serious Interferes with Treatment completion | Serious mental illness Interferes with Treatment completion

Type de données

boolean

Alias
UMLS CUI [1,1]
C0221423
UMLS CUI [1,2]
C0205404
UMLS CUI [1,3]
C0521102
UMLS CUI [1,4]
C0580352
UMLS CUI [2,1]
C3841614
UMLS CUI [2,2]
C0521102
UMLS CUI [2,3]
C0580352
9. history of poor compliance or history of drug/alcohol abuse, or excessive alcohol consumption that would interfere with the ability to comply with the study protocol,
Description

Poor compliance Interferes with Protocol Compliance | Substance Use Disorders Interfere with Protocol Compliance | Alcohol intake above recommended sensible limits Interferes with Protocol Compliance

Type de données

boolean

Alias
UMLS CUI [1,1]
C0032646
UMLS CUI [1,2]
C0521102
UMLS CUI [1,3]
C0525058
UMLS CUI [2,1]
C0038586
UMLS CUI [2,2]
C0521102
UMLS CUI [2,3]
C0525058
UMLS CUI [3,1]
C0560219
UMLS CUI [3,2]
C0521102
UMLS CUI [3,3]
C0525058
10. severe asthma, allergy, other autoimmune disease or any condition that the physician judges could be detrimental to subjects participating in this study; including deviations deemed clinically important from normal clinical laboratory
Description

Severe asthma | Severe allergy | Autoimmune Disease Severe | Condition Study Subject Participation Status Unfavorable | Laboratory test result abnormal

Type de données

boolean

Alias
UMLS CUI [1]
C0581126
UMLS CUI [2]
C2945656
UMLS CUI [3,1]
C0004364
UMLS CUI [3,2]
C0205082
UMLS CUI [4,1]
C0348080
UMLS CUI [4,2]
C2348568
UMLS CUI [4,3]
C3640815
UMLS CUI [5]
C0438215
previous treatment
Description

Prior Therapy

Type de données

boolean

Alias
UMLS CUI [1]
C1514463
1. treatment with interferon or glatiramer acetate or immunosuppressive drugs within 26 weeks prior to baseline
Description

Interferon | Glatiramer acetate | Immunosuppressive Agents

Type de données

boolean

Alias
UMLS CUI [1]
C3652465
UMLS CUI [2]
C0289884
UMLS CUI [3]
C0021081
2. treatment with bone marrow transplantation, total lymphoid irradiation, monoclonal antibodies, umbilical cord stem cells, aimspro at any time prior to baseline
Description

Bone Marrow Transplantation | Lymphatic Irradiation Total | Monoclonal Antibodies | Umbilical Cord Blood Stem Cell | Other Coding

Type de données

boolean

Alias
UMLS CUI [1]
C0005961
UMLS CUI [2,1]
C0024230
UMLS CUI [2,2]
C0439810
UMLS CUI [3]
C0003250
UMLS CUI [4]
C1710528
UMLS CUI [5]
C3846158
3. treatment with corticosteroids or acth within 4 weeks prior to baseline
Description

Adrenal Cortex Hormones | Corticotropin

Type de données

boolean

Alias
UMLS CUI [1]
C0001617
UMLS CUI [2]
C0001655
4. treatment with any investigational agent within 12 weeks prior to baseline
Description

Investigational New Drugs

Type de données

boolean

Alias
UMLS CUI [1]
C0013230

Similar models

Eligibility Multiple Sclerosis NCT00630383

Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
Item Group
C1512693 (UMLS CUI)
Multiple Sclerosis, Relapsing-Remitting | Secondary Progressive Multiple Sclerosis Associated with Relapses | MRI scan Consistent with Multiple Sclerosis
Item
1. patients with documented multiple sclerosis relapsing remitting or secondary progressive with relapses, according to mcdonald's criteria, and an mri scan consistent with ms according to fazekas criteria
boolean
C0751967 (UMLS CUI [1])
C0751965 (UMLS CUI [2,1])
C0332281 (UMLS CUI [2,2])
C0035020 (UMLS CUI [2,3])
C0024485 (UMLS CUI [3,1])
C0332290 (UMLS CUI [3,2])
C0026769 (UMLS CUI [3,3])
Relapse Quantity
Item
2. patients with at least 1 relapse in the last 12 months
boolean
C0035020 (UMLS CUI [1,1])
C1265611 (UMLS CUI [1,2])
EDSS
Item
3. patients with edss score in the range of 0 to 5.5 at the baseline visit
boolean
C0451246 (UMLS CUI [1])
Age
Item
4. patients of both genders, age >18 years and < 60 years
boolean
C0001779 (UMLS CUI [1])
Childbearing Potential Pregnancy test negative | Childbearing Potential Contraceptive methods
Item
5. women of child bearing potential, (who have a negative pregnancy test) must agree to use methods of medically acceptable forms of contraception during the study.
boolean
C3831118 (UMLS CUI [1,1])
C0427780 (UMLS CUI [1,2])
C3831118 (UMLS CUI [2,1])
C0700589 (UMLS CUI [2,2])
Protocol Compliance
Item
6. be able and willing to comply with study visits and procedures per protocol.
boolean
C0525058 (UMLS CUI [1])
Informed Consent
Item
7. understand, sign, and date the written voluntary informed consent form at the screening visit prior to any protocol-specific procedures performed.
boolean
C0021430 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
At risk Illness Severe | At risk Death
Item
no populations at risk of severe illness or death will be included in this study
boolean
C1444641 (UMLS CUI [1,1])
C0221423 (UMLS CUI [1,2])
C0205082 (UMLS CUI [1,3])
C1444641 (UMLS CUI [2,1])
C0011065 (UMLS CUI [2,2])
Life Expectancy
Item
1. life expectancy < 6 months.
boolean
C0023671 (UMLS CUI [1])
Malignant Neoplasms Free of Duration | Exception Basal cell carcinoma | Exception Carcinoma in situ of uterine cervix
Item
2. patient is < 5 years free of malignancy, except treated basal cell skin cancer or cervical carcinoma in situ.
boolean
C0006826 (UMLS CUI [1,1])
C0332296 (UMLS CUI [1,2])
C0449238 (UMLS CUI [1,3])
C1705847 (UMLS CUI [2,1])
C0007117 (UMLS CUI [2,2])
C1705847 (UMLS CUI [3,1])
C0851140 (UMLS CUI [3,2])
Cardiac problem New York Heart Association Classification | Congestive heart failure | Myocardial Infarction
Item
3. patient with grade iii/iv cardiac problems as defined by the new york heart association criteria. (i.e., congestive heart failure, myocardial infarction within 6 months of study)
boolean
C0262402 (UMLS CUI [1,1])
C1275491 (UMLS CUI [1,2])
C0018802 (UMLS CUI [2])
C0027051 (UMLS CUI [3])
Medical condition Severe Uncontrolled | Medical condition Uncontrolled
Item
4. patients with severe and/or uncontrolled medical condition.
boolean
C3843040 (UMLS CUI [1,1])
C0205082 (UMLS CUI [1,2])
C0205318 (UMLS CUI [1,3])
C3843040 (UMLS CUI [2,1])
C0205318 (UMLS CUI [2,2])
HIV Infection
Item
5. patient has a known diagnosis of human immunodeficiency virus (hiv) infection.
boolean
C0019693 (UMLS CUI [1])
Anemia | Hemoglobin measurement | Gender
Item
6. anaemia (hb <10 g/dl for females, <11 g/dl for males)
boolean
C0002871 (UMLS CUI [1])
C0518015 (UMLS CUI [2])
C0079399 (UMLS CUI [3])
Parasitic infection | Anthelmintics
Item
7. prior or present evidence of parasitic infection; prior treatment with anti-helminthic drugs
boolean
C0747256 (UMLS CUI [1])
C0003158 (UMLS CUI [2])
Illness Serious Interferes with Treatment completion | Serious mental illness Interferes with Treatment completion
Item
8. patient with serious medical or psychiatric illness that could potentially interfere with the completion of the study treatment according to this protocol
boolean
C0221423 (UMLS CUI [1,1])
C0205404 (UMLS CUI [1,2])
C0521102 (UMLS CUI [1,3])
C0580352 (UMLS CUI [1,4])
C3841614 (UMLS CUI [2,1])
C0521102 (UMLS CUI [2,2])
C0580352 (UMLS CUI [2,3])
Poor compliance Interferes with Protocol Compliance | Substance Use Disorders Interfere with Protocol Compliance | Alcohol intake above recommended sensible limits Interferes with Protocol Compliance
Item
9. history of poor compliance or history of drug/alcohol abuse, or excessive alcohol consumption that would interfere with the ability to comply with the study protocol,
boolean
C0032646 (UMLS CUI [1,1])
C0521102 (UMLS CUI [1,2])
C0525058 (UMLS CUI [1,3])
C0038586 (UMLS CUI [2,1])
C0521102 (UMLS CUI [2,2])
C0525058 (UMLS CUI [2,3])
C0560219 (UMLS CUI [3,1])
C0521102 (UMLS CUI [3,2])
C0525058 (UMLS CUI [3,3])
Severe asthma | Severe allergy | Autoimmune Disease Severe | Condition Study Subject Participation Status Unfavorable | Laboratory test result abnormal
Item
10. severe asthma, allergy, other autoimmune disease or any condition that the physician judges could be detrimental to subjects participating in this study; including deviations deemed clinically important from normal clinical laboratory
boolean
C0581126 (UMLS CUI [1])
C2945656 (UMLS CUI [2])
C0004364 (UMLS CUI [3,1])
C0205082 (UMLS CUI [3,2])
C0348080 (UMLS CUI [4,1])
C2348568 (UMLS CUI [4,2])
C3640815 (UMLS CUI [4,3])
C0438215 (UMLS CUI [5])
Prior Therapy
Item
previous treatment
boolean
C1514463 (UMLS CUI [1])
Interferon | Glatiramer acetate | Immunosuppressive Agents
Item
1. treatment with interferon or glatiramer acetate or immunosuppressive drugs within 26 weeks prior to baseline
boolean
C3652465 (UMLS CUI [1])
C0289884 (UMLS CUI [2])
C0021081 (UMLS CUI [3])
Bone Marrow Transplantation | Lymphatic Irradiation Total | Monoclonal Antibodies | Umbilical Cord Blood Stem Cell | Other Coding
Item
2. treatment with bone marrow transplantation, total lymphoid irradiation, monoclonal antibodies, umbilical cord stem cells, aimspro at any time prior to baseline
boolean
C0005961 (UMLS CUI [1])
C0024230 (UMLS CUI [2,1])
C0439810 (UMLS CUI [2,2])
C0003250 (UMLS CUI [3])
C1710528 (UMLS CUI [4])
C3846158 (UMLS CUI [5])
Adrenal Cortex Hormones | Corticotropin
Item
3. treatment with corticosteroids or acth within 4 weeks prior to baseline
boolean
C0001617 (UMLS CUI [1])
C0001655 (UMLS CUI [2])
Investigational New Drugs
Item
4. treatment with any investigational agent within 12 weeks prior to baseline
boolean
C0013230 (UMLS CUI [1])

Utilisez ce formulaire pour les retours, les questions et les améliorations suggérées.

Les champs marqués d’un * sont obligatoires.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial